BioVie Presents Data Highlighting Role Of Insulin Resistance And Neuroinflammation In The Development Of Mild To Moderate In Alzheimer's Disease
Portfolio Pulse from Happy Mohamed
BioVie Inc. presented baseline data from its Phase 3 study of NE3107, an anti-inflammatory insulin sensitizer, in patients with mild to moderate Alzheimer's Disease at the American Diabetes Association's 83rd Scientific Sessions. The study aims to evaluate the safety and efficacy of NE3107 in treating Alzheimer's Disease.
June 26, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioVie's Phase 3 study of NE3107, an anti-inflammatory insulin sensitizer, aims to evaluate its safety and efficacy in treating Alzheimer's Disease.
The presentation of baseline data from BioVie's Phase 3 study of NE3107 highlights the company's progress in developing a potential treatment for Alzheimer's Disease. Positive results from the study could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100